Hepatitis C: Host and Viral Factors Associated with Response to Therapy and Progression of Liver Fibrosis

Jovanović-Ćupić, Snežana; Božović, Ana; Krajnović, Milena; NinaPetrovic,

doi:10.5772/intechopen.76417

Cited by 3 publications

(3 citation statements)

References 115 publications

(137 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 1 ] The prevalence of chronic HCV is estimated to be 1.1% with high variation in different regions of the world. [ 2 3 ] The prevalence in general population varies between 0.5 to 6.5% with 0.5–15% variation in western countries. In southeast Asia and Mediterranean regions, the prevalence reaches up to 2.3% while in Europe it is around 1.5.…”

Section: Introductionmentioning

confidence: 99%

Predictive factors for acquiring HCV infection in the population residing in high endemic, resource-limited settings

Khan

Shah

Ashraf

2021

Journal of Family Medicine and Primary Care

View full text Add to dashboard Cite

Background: In a country like Pakistan, a high prevalence of HCV persists due to a lack of awareness among the masses and the absence of adequate medical facilities in less privileged areas. Therefore, this study aimed to develop a risk-based screening tool based on the identification of predictive factors for HCV in the adult population in Karachi, Pakistan, which can later be validated for implementation. Methodology: A case-control study design was adopted and data was collected through an interview-based questionnaire from among 284 patients visiting the Family Medicine Department at The Indus Hospital, Karachi on whom the anti-HCV antibody test was conducted. Received data was then entered and analyzed using Statistical Package for the Social Sciences (SPSS) version 21.0. Result: Analysis indicated that in the entire cohort, marital status, employment status, history of being operated on in the past, family history of HCV infection, and body piercing were the factors significantly associated with positive HCV antibody. Results thus achieved show that the anti-HCV-positive rate was higher in ever married, employed, having had surgery, and family history of HCV infection (aOR: 2.42, 3.5, 2.04 and 2.5, P = 0.043, 0.002, 0.011 and 0.005, respectively). Conclusions: It is concluded that future research may be conducted enrolling the heterogeneous population to further probe the HCV burden and incidence in our society to initiate educational purposes. This goal can be achieved through commercial advertisements and free public lectures for disease prevention and better health awareness among the masses and the curers.

show abstract

Section: Introductionmentioning

confidence: 99%

Predictive factors for acquiring HCV infection in the population residing in high endemic, resource-limited settings

Khan

Shah

Ashraf

2021

Journal of Family Medicine and Primary Care

View full text Add to dashboard Cite

show abstract

“…Rates ranging from 88.3 to 100% have been reported in literature [25][26][27][28][29]. Historically, RVR has been a predictor of healing [30,31]. The different treatment regimens in our study did not affect the virological response.…”

Section: Discussionmentioning

confidence: 43%

Efficacy and Safety of Sofosbuvir-Based Regimens in Patients with Viral Hepatitis C and Stage 4 and 5 Chronic Kidney Disease: The Cameroon Experience

Martial Tsiazok,

Mathurin Pierre,

Aristide Eric Nono

et al. 2023

J Clin Nephrol Ren Care

View full text Add to dashboard Cite

Background and objectives:Treatment of viral hepatitis C in chronic kidney disease patients with glomerular filtration rate < 30 ml/min/1.73 m 2 remains a challenge in countries with combinations containing only sofosbuvir. We investigated the efficacy and safety of sofosbuvir based regimens in patients infected with hepatitis C virus and stage 4 and 5 chronic kidney disease. Methods:We conducted a multicentric, retrospective study of patients records treated for viral hepatitis C and chronic kidney disease. We collected data on adverse events, renal function during and after treatment, and virological response during and after treatment. Results:We recruited 28 patients, including 13 patients on maintenance haemodialysis and 17 men. The mean age was 60.68 ± 13.00 years. Cirrhosis was found in 12 (43%) patients. The genotypes found were 1, 2 and 4. There were 27 (96.4%) treatment-naïve patients. The different combinations found were: Sofosbuvir 400 mg twice a week + ribavirin 200 mg daily (3.6%, n = 1), sofosbuvir 400 mg + daclatasvir 60 mg daily (21.6%, n = 6), sofosbuvir 400 mg + ledipasvir 90 mg daily in two patients, twice a week in 9 patients and three times a week in one patient (43.2%, n = 12), sofosbuvir 400 mg + velpatasvir 100 mg daily in 6 patients, twice weekly in three patients (32.4%, n = 9). The sustained virological response rate was 100% in the 21 patients who did viral load after treatment. The main adverse events were nausea (10.7%), vomiting (10.7%), dizziness (7.1%), headache (7.1%) and pruritus (7.1%). The glomerular filtration rate was 22.3 ± 5.7 ml/min/1.73 m 2 at the start of treatment, 17.7 ± 4 ml/min/1.73 m 2 at the end of treatment and 20.7 ± 5.3 ml/min/1.73 m 2 three months after treatment. Conclusion:Treatment with sofosbuvir-containing regimens is effective and well tolerated in patients infected with hepatitis C virus and stage 4 and 5 chronic kidney disease.

show abstract

“…Moreover, there is evidence that RUNX3 methylation is higher in HCV-related HCC than in non-HCV-related HCC [ 169 ]. HCV is known to be involved in hepatocarcinogenesis through a complex epigenetic network, including altered host DNA methylation patterns and deregulated expression of histone modifiers and specific miRNAs (reviewed in [ 170 ]). Future studies should also focus on the molecular characterisation of HCC in the contest of their specific aetiology.…”

Section: Discussionmentioning

confidence: 99%

Multiple Roles of the RUNX Gene Family in Hepatocellular Carcinoma and Their Potential Clinical Implications

Krajnović,

Kožik,

Božović

et al. 2023

Cells

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most frequent cancers in humans, characterised by a high resistance to conventional chemotherapy, late diagnosis, and a high mortality rate. It is necessary to elucidate the molecular mechanisms involved in hepatocarcinogenesis to improve diagnosis and treatment outcomes. The Runt-related (RUNX) family of transcription factors (RUNX1, RUNX2, and RUNX3) participates in cardinal biological processes and plays paramount roles in the pathogenesis of numerous human malignancies. Their role is often controversial as they can act as oncogenes or tumour suppressors and depends on cellular context. Evidence shows that deregulated RUNX genes may be involved in hepatocarcinogenesis from the earliest to the latest stages. In this review, we summarise the topical evidence on the roles of RUNX gene family members in HCC. We discuss their possible application as non-invasive molecular markers for early diagnosis, prognosis, and development of novel treatment strategies in HCC patients.

show abstract

Hepatitis C: Host and Viral Factors Associated with Response to Therapy and Progression of Liver Fibrosis

Cited by 3 publications

References 115 publications

Predictive factors for acquiring HCV infection in the population residing in high endemic, resource-limited settings

Predictive factors for acquiring HCV infection in the population residing in high endemic, resource-limited settings

Efficacy and Safety of Sofosbuvir-Based Regimens in Patients with Viral Hepatitis C and Stage 4 and 5 Chronic Kidney Disease: The Cameroon Experience

Multiple Roles of the RUNX Gene Family in Hepatocellular Carcinoma and Their Potential Clinical Implications

Contact Info

Product

Resources

About